Saturday 17 October 2026
Export ATRA’s income statement to Excel — free account
Atara Biotherapeutics, Inc.
ATRA Healthcare Biotechnology
Atara Biotherapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $120.8 million, down 6.33% from fiscal 2024. In the quarter to June 2026, revenue fell 96.4%, EPS fell 260.0% and free cash flow grew 52.1%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years; insiders bought in the last twelve months.
9.18
0.47
−4.87%
Follow ATRA
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 5.72 |
Piotroski F-Score |
— | — | — | — | — | — | — | 2 | 5 | 5 |
P/S ratio |
— | — | — | — | — | 72.58 | 5.26 | 5.93 | 0.77 | 1.88 |
Altman Z-Score |
— | — | — | — | — | (1.32) | (7.09) | (22.28) | (28.18) | (125.91) |
Altman Z″-Score (non-manufacturers) |
— | — | — | — | — | (9.62) | (15.37) | — | (71.22) | (315.39) |
P/FCF ratio |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
— | — | — | — | — | (43.08) | (5.88) | (1.01) | (4.07) | (39.83) |
Beneish M-Score |
— | — | — | — | — | — | 11.96 | — | 7.89 | 16.88 |
P/B ratio |
— | — | — | — | — | 5.28 | 2.64 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
— | — | — | — | — | 5.28 | 2.64 | 0.00 | 0.00 | 0.00 |
EV/Sales |
— | — | — | — | — | 54.33 | 1.44 | (0.12) | 0.44 | 1.81 |
EV/EBITDA |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 5.71 |
EV/Operating CF |
— | — | — | — | — | (5.01) | (0.34) | 0.01 | (0.83) | (4.29) |
EV/FCF |
— | — | — | — | — | (4.78) | (0.33) | 0.01 | (0.83) | (4.36) |
Quick Ratio |
26.45 | 6.02 | 7.75 | 7.06 | 6.06 | 3.52 | 3.59 | 0.60 | 0.33 | 0.65 |
Current Ratio |
26.93 | 6.23 | 8.04 | 7.43 | 6.31 | 3.64 | 3.74 | 0.72 | 0.48 | 0.82 |
Net Debt/EBITDA |
3.27 | 1.39 | 1.32 | 0.89 | 1.67 | 1.13 | 0.89 | 0.19 | 0.54 | (0.22) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.15 | 0.03 | 0.94 | 1.87 |
Operating CF/Net income |
0.76 | 0.73 | 0.78 | 0.81 | 0.59 | 0.65 | 1.18 | 0.70 | 0.80 | (1.56) |
Capex/Depreciation |
(1.02) | (11.99) | (19.45) | (0.97) | (0.49) | (0.95) | (0.63) | (0.21) | (0.05) | 0.40 |
Interest Coverage |
(36.88) | — | — | — | — | — | (752.05) | (52.22) | (18.08) | 9.46 |
| (27.79%) | (55.37%) | (89.29%) | (92.43%) | (81.43%) | (91.69%) | (112.39%) | (2,014.86%) | 86.92% | (48.15%) | |
| (26.85%) | (49.61%) | (75.69%) | (79.20%) | (65.86%) | (64.41%) | (54.06%) | (101.91%) | (62.20%) | 50.55% | |
ROIC |
0.00% | (656.28%) | (510.45%) | (587.08%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(31.10%) | (63.33%) | (65.90%) | (100.19%) | (62.46%) | (102.26%) | (102.62%) | 756.49% | 124.88% | (1,239.59%) |
Average Days of Receivables |
— | — | — | — | 0.00 | 17.69 | 230.93 | 1,452.17 | 4.20 | 3.79 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1,386.44% | 428.69% | 2,622.01% | 117.48% | 31.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 387.42% | 112.55% | 593.82% | 30.93% | 21.74% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 264.82% | 84.69% | 529.41% | 20.94% | 8.07% |
Graham Net Nets |
— | — | — | — | — | 0.13 | 0.14 | (3.20) | (1.42) | (0.20) |
Graham Number |
— | — | — | — | — | 0.00 | 0.00 | 185.81 | 61.57 | 0.00 |
Earnings Yield |
— | — | — | — | — | (23.03%) | (67.99%) | (545.83%) | (97.45%) | 17.47% |
Free Cash Flow Yield |
— | — | — | — | — | (15.65%) | (82.09%) | (381.99%) | (69.19%) | (22.07%) |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.43 | 15.58 | 2.02 | 17.22 | 9.63 |
Operating CF per Share |
(52.23) | (73.25) | (102.59) | (114.81) | (61.09) | (58.86) | (66.29) | (45.56) | (9.18) | (4.06) |
Capex per Share |
(2.63) | (16.94) | (20.50) | (2.71) | (1.53) | (2.82) | (1.03) | (0.28) | (0.03) | 0.08 |
Free Cash Flow per Share |
(54.86) | (90.19) | (123.09) | (117.53) | (62.62) | (61.68) | (67.32) | (45.84) | (9.21) | (3.99) |
Cash per Share |
222.64 | 139.21 | 176.80 | 126.35 | 169.27 | 99.09 | 59.56 | 12.25 | 5.69 | 0.68 |
Shareholders Equity per Share |
220.77 | 148.90 | 193.37 | 141.69 | 156.25 | 74.63 | 31.04 | (23.43) | (12.99) | (3.07) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
220.77 | 148.90 | 193.37 | 141.69 | 156.25 | 74.63 | 31.04 | (23.43) | (12.99) | (3.07) |
Free Cash Flow |
(63.04) | (107.73) | (215.70) | (241.20) | (185.27) | (231.10) | (274.62) | (194.17) | (68.96) | (49.99) |
Working Capital |
250.88 | 144.54 | 281.51 | 236.25 | 440.37 | 278.84 | 216.16 | (40.36) | (69.68) | (2.71) |
Capital Expenditures |
(3.02) | (20.23) | (35.92) | (5.57) | (4.51) | (10.58) | (4.19) | (1.20) | (0.25) | 0.95 |
Net Current Asset Value |
250.38 | 132.28 | 268.51 | 220.83 | 397.49 | 196.11 | 45.30 | (162.87) | (141.49) | (46.52) |
EV/EBIT |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 6.09 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.52 | 0.07 | 0.14 | 0.00 | (0.01) |
Price to Operating Income |
— | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 6.33 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.91 | 0.04 | 0.03 | 0.11 | 0.18 | 0.21 | 1.06 | 1.46 | 3.72 | 32.53 |
Cash ROIC |
(12.37%) | (31.30%) | (33.25%) | (43.85%) | (19.24%) | (35.51%) | (74.30%) | 410.00% | 126.21% | 166.53% |
Accounts Receivable Turnover |
— | — | — | — | 0.00 | 18.19 | 3.09 | 0.23 | 7.25 | 88.32 |
Accounts Payable Turnover |
0.18 | 0.11 | 0.41 | 1.39 | 1.31 | 0.93 | 1.20 | 1.68 | 5.22 | 9.44 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.57 | 2.06 | 0.00 |
Average Days of Payables |
2,647.44 | 5,616.65 | 359.01 | 358.61 | 263.31 | 557.06 | 172.15 | 151.32 | 75.87 | 2.19 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 39.74 | 398.68 | 185.11 | 0.00 |
Average Receivables |
— | — | — | — | 1.12 | 1.12 | 20.60 | 37.16 | 17.80 | 1.37 |
Average Payables |
2.11 | 8.74 | 9.22 | 5.84 | 7.54 | 12.24 | 12.12 | 5.28 | 4.03 | 2.25 |
Average Inventory |
— | — | — | — | — | — | — | 5.65 | 10.18 | — |
Average Assets |
294.44 | 240.85 | 304.81 | 367.39 | 465.53 | 528.12 | 422.27 | 270.96 | 137.30 | 64.67 |
Average Common Equity |
284.42 | 215.80 | 258.36 | 314.82 | 376.56 | 370.98 | 203.13 | 13.70 | (98.26) | (67.89) |
Columns are period end dates